Efficacy of methylphenidate treatment in childhood myotonic dystrophy type 1 and comorbid attention deficit hyperactivity disorder: A case report using eye tracking assessment

IF 1.4 4区 医学 Q4 CLINICAL NEUROLOGY
Dirk J.J. Sweere , Jos G.M. Hendriksen , R. Jeroen Vermeulen , Sylvia Klinkenberg
{"title":"Efficacy of methylphenidate treatment in childhood myotonic dystrophy type 1 and comorbid attention deficit hyperactivity disorder: A case report using eye tracking assessment","authors":"Dirk J.J. Sweere ,&nbsp;Jos G.M. Hendriksen ,&nbsp;R. Jeroen Vermeulen ,&nbsp;Sylvia Klinkenberg","doi":"10.1016/j.braindev.2023.11.004","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p><span>Despite the increased prevalence of comorbid attention deficit hyperactivity disorder<span> (ADHD) in children with myotonic dystrophy type 1<span>, the effects of methylphenidate<span><span> treatment on associated </span>cognitive deficits in this population is not yet investigated. </span></span></span></span><em>Case:</em><span> We describe a case study of an eleven-year-old male patient with myotonic dystrophy type 1 and comorbid ADHD that was treated with methylphenidate in a twice daily regime (0.60 mg/kg/day). Positive effects on learning and cognition were reported by the parents and teachers. No negative side effects were reported. Sequential neuropsychological assessments before and 45 minutes after methylphenidate intake were conducted to quantify the cognitive effects of methylphenidate treatment. Significant improvements in regulation of attention were behaviorally observed and were quantified using eye tracking technology. </span><em>Conclusion:</em> We conclude that methylphenidate may be an effective treatment for ADHD-related cognitive deficits and learning difficulties in children with myotonic dystrophy type 1 which merits further research.</p></div>","PeriodicalId":56137,"journal":{"name":"Brain & Development","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2023-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brain & Development","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0387760423001742","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

Despite the increased prevalence of comorbid attention deficit hyperactivity disorder (ADHD) in children with myotonic dystrophy type 1, the effects of methylphenidate treatment on associated cognitive deficits in this population is not yet investigated. Case: We describe a case study of an eleven-year-old male patient with myotonic dystrophy type 1 and comorbid ADHD that was treated with methylphenidate in a twice daily regime (0.60 mg/kg/day). Positive effects on learning and cognition were reported by the parents and teachers. No negative side effects were reported. Sequential neuropsychological assessments before and 45 minutes after methylphenidate intake were conducted to quantify the cognitive effects of methylphenidate treatment. Significant improvements in regulation of attention were behaviorally observed and were quantified using eye tracking technology. Conclusion: We conclude that methylphenidate may be an effective treatment for ADHD-related cognitive deficits and learning difficulties in children with myotonic dystrophy type 1 which merits further research.

哌醋甲酯治疗儿童1型肌强直性营养不良和合并症注意缺陷多动障碍的疗效:用眼动追踪评估一例报告
导读:尽管在1型肌强直性营养不良儿童中,共病性注意缺陷多动障碍(ADHD)的患病率有所增加,但哌醋甲酯治疗对该人群相关认知缺陷的影响尚未研究。病例:我们描述了一个病例研究,一个11岁的男性患者患有1型肌强直性营养不良和共病性多动症,用哌醋甲酯治疗,每天两次(0.60 mg/kg/天)。家长和老师对学习和认知有积极的影响。没有负面副作用的报道。在服用哌甲酯之前和服用后45分钟进行连续的神经心理学评估,以量化哌甲酯治疗的认知效果。注意调节的显著改善被行为观察到,并使用眼动追踪技术进行量化。结论:我们认为哌甲酯可能是治疗1型肌强直性营养不良儿童adhd相关认知缺陷和学习困难的有效方法,值得进一步研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Brain & Development
Brain & Development 医学-临床神经学
CiteScore
3.60
自引率
0.00%
发文量
153
审稿时长
50 days
期刊介绍: Brain and Development (ISSN 0387-7604) is the Official Journal of the Japanese Society of Child Neurology, and is aimed to promote clinical child neurology and developmental neuroscience. The journal is devoted to publishing Review Articles, Full Length Original Papers, Case Reports and Letters to the Editor in the field of Child Neurology and related sciences. Proceedings of meetings, and professional announcements will be published at the Editor''s discretion. Letters concerning articles published in Brain and Development and other relevant issues are also welcome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信